NASDAQ:CLOV 24 October 2025 - 11 June 2026

Clover Health Investments, Corp. shares are up as the company finally got clarity on a key question hanging over its 2027 forecast: would its main Medicare Advantage plan land at 3.5 or 4.5 stars? Investors got an answer this week. On June 10, Clover said in a Form 8-K that CMS bumped the 2026 Star Rating for Contract H5141, its PPO plan, to 4.5 stars. The move follows a federal judge tossing the earlier 3.5-star rating. Clover shares ended Wednesday at $4.89, up 13.99% on the day, giving the company a market cap of roughly $2.58 billion. Early Thursday, StockAnalysis showed CLOV at $5.29 in premarket activity, up another 8.18%. Google Finance put the stock’s 52-week high at $5.14, with that level reached as shares spiked.

Stock Performance: Clover Health stock has been exceptionally volatile in mid‑October 2025. On Oct. 21 it jumped ~8.7% intraday to ~$3.20 Marketbeat, and on Oct. 24 it spiked another ~18%, trading near $3.79 Reuters. According to Reuters data, that surge propelled CLOV close to its 52-week high and far above its recent 50‑day moving average Marketbeat. The 200-day average was also eclipsed, signaling strong upward momentum Marketbeat. This rally has come on unusually heavy volume Reuters, reflecting frenzied buying. By contrast, the stock was languishing near multi-year lows just a few months ago, underscoring the swing. Overall, CLOV’s high beta and large short interest mean it tends to move sharply on news and market sentiment Marketbeat Fintel. Analyst Views: Wall Street opinions on CLOV remain split. Last week Zacks Research upgraded Clover to a #2 rank, noting that upward revisions in earnings estimates tend to propel stock gains Finviz. MarketBeat reports that Canaccord Genuity cut its target to $4.10 and UBS lowered its target to $3.00 in early October Marketbeat. Two analysts have Buy ratings and two have Hold Marketbeat, yielding a consensus “Hold” stance. The five‑analyst average price target is about $4.03 Marketbeat, slightly above current levels. Notably, Weiss